Recent Quotes

Aptevo Therapeutics Inc is a clinical-stage biotechnology company. It focuses on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. The company develops its drug candidates using its ADAPTIR platform. The products under its pipeline are APVO436, which targets CD123 and CD3 and redirects T-cell cytotoxicity to the tumor; ALG.APV-527, for the treatment of a broad spectrum of cancers over-expressing the 5T4 tumor antigen, including mesothelioma, non-small-cell-lung, head & neck, pancreatic, renal, ovarian, and bladder cancers; and APVO603.

Earnings

Q2 2021		Est.		Actual		Surprise
EPS		(EXPECTED)2021-08-13
REV		(EXPECTED)2021-08-13

Q1 2021		Est.		Actual		Surprise
EPS		1.690		-1.740		-3.4300
REV		2.420M		2.421M		1.000K

Analyst Ratings

Date	Analyst Firm	Analyst Name	Action	Rating	Action Price	Prior Price	Target

Related Companies

Ticker	Company	Price	Change	Chg %		Mkt Cap
APVO	Aptevo Therapeutics	20.77	1.38	7.12%		86.3M

Aptevo Therapeutics Frequently Asked Questions

How do I buy Aptevo Therapeutics (APVO) stock?

You can purchase shares of Aptevo Therapeutics (NASDAQ: APVO) through any online brokerage.

View our list of the best stock brokerages.

Who are Aptevo Therapeutics's (APVO) competitors?

Other companies in Aptevo Therapeutics’s space includes: Cleveland BioLabs (NASDAQ:CBLI), Eledon Pharmaceuticals (NASDAQ:ELDN), Aziyo Biologics (NASDAQ:AZYO), AIkido Pharma (NASDAQ:AIKI) and ImmuCell (NASDAQ:ICCC).

What is the target price for Aptevo Therapeutics (APVO) stock?

The latest price target for Aptevo Therapeutics (NASDAQ: APVO) was reported by Roth Capital on May 28, 2021. The analyst firm set a price target for 50.00 expecting APVO to rise to within 12 months (a possible 157.86% upside). 2 analyst firms have reported ratings in the last year.

Current Stock Price for Aptevo Therapeutics (APVO)?

The stock price for Aptevo Therapeutics (NASDAQ: APVO) is $19.39 last updated Today at 8:00:02 PM.

Does Aptevo Therapeutics (APVO) pay a dividend?

There are no upcoming dividends for Aptevo Therapeutics.

When is Aptevo Therapeutics (NASDAQ:APVO) reporting earnings?

Aptevo Therapeutics’s Q2 earnings are confirmed for after-market on August 13, 2021.

Is Aptevo Therapeutics (APVO) going to split?

There is no upcoming split for Aptevo Therapeutics.

What sector and industry does Aptevo Therapeutics (APVO) operate in?

Aptevo Therapeutics is in the Consumer Discretionary sector and Multiline Retail industry. They are listed on the NASDAQ.